Jan 07, 2025
Lilly to participate in J.P. Morgan Healthcare Conference
Dec 20, 2024
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Dec 17, 2024
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
Dec 17, 2024
Lilly's Kisunla(TM) (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Dec 13, 2024
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
Dec 11, 2024
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
Dec 09, 2024
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade
Dec 09, 2024
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
Dec 09, 2024
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
Dec 05, 2024
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
Dec 04, 2024
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Nov 19, 2024
Lilly announces changes on board of directors
Nov 18, 2024
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Nov 16, 2024
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
Nov 13, 2024
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Nov 05, 2024
Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
Nov 01, 2024
Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
Oct 29, 2024
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study
Oct 28, 2024
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
Oct 28, 2024
Lilly declares fourth-quarter 2024 dividend